February 18, 2018

MultiplexDX is about to close an investment round – join us

 

We founded MutiplexDX two years ago with a vision to make our unique cancer diagnostics a world-wide standard. Our method brings the most accurate, fastest and affordable cancer diagnostics and enables personalized medical treatment increasing number of people who survive cancer. We believe reaching such a goal doesn’t necessarily have to be done only from donations but can actually create a sustainable business. We are currently finalizing our investment round which should not only bring us capital to go faster. It should also bring smart investors who will help us reach the goal with their experience, know-how and network.

  • Target: eliminate incorrect cancer diagnosis and save more lives thanks to the 99% accuracy of the personalised diagnostic method
  • EUR 120k turnover with the existing product portfolio in a pilot phase
  • Customers include the National Institute of HealthAlbert Einstein College of Medicine, Düsseldorf Universitätsklinikum, Cornell University, The Rockefeller University, Vanderbilt University
  • Team: renowned specialists in the field of biochemistry, biology and biophysics with experience from leading global research institutions including Rockefeller University and the National Cancer Institute, as well as pharmaceutical companies

We are raising capital via Crowdberry, TO JOIN MULTIPLEXDX, contact us at info@multiplexdx.com or go to www.crowdberry.eu/en/multiplexdx where you will find the investment documentation.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter, Google +

Other 

MultiplexDX News